Pharmacotherapy for obesity has also shown effectiveness in real-world settings, with the most recent FDA approvals including semaglutide and tirzepatide. The authors note that obesity medications are underprescribed, and they identified the likely reasons for underutilizing these therapies, which included knowledge gaps, concerns about safety, and coverage limitations. They noted that the recent approval of semaglutide to reduce the risk of cardiovascular death, heart attack, and stroke for patients with CVD and either obesity or overweight has potential steer the conversation of obesity medication as a way to manage medical complications opposed to weight management.1
The authors also discussed metabolic and bariatric surgery, which they stated is a last-line therapy for severe obesity. The surgery was first introduced in the 1950s but has since become safer and more effective, and has lower risks for CVD incidents, adverse pregnancy outcomes, and other obesity-associated conditions. Further, the authors said that among patients with preexisting type 2 diabetes or CVD, patients also experienced improvements in glycemic parameters and cardiac structure and function.1
However, the authors said that a challenge in surgery for patients is access, which should be addressed, especially since the disparities are well established for severe obesity. For example, adolescents and adults who identify as Black or Hispanic/Latinx and those who have fewer social economic resources are less likely to undergo surgery, and the social perception of surgery for obesity is also a barrier to access, the authors said.1
The study authors also provided existing and emerging opportunities to address the gaps in clinical practice, including increasing physician training and facilitating referrals to obesity medicine specialists. Additionally, physicians need to be more comfortable and sensitive to weight-management discussions, which can be improved with training, referrals, and by engaging community health workers for diverse populations who are underrepresented in care. As for coverage, the authors stated that increasing reimbursement for all obesity management options and increasing support for patient access is essential to address gaps in care.1
The authors also emphasized the importance of addressing the stigma surrounding obesity, which they said could be done with sensitivity training, utilizing telemedicine to improve adherence, and to establish their clinics as a safe space for patients.1
Key Takeaways
- Despite progress in understanding obesity, translating this knowledge into effective treatment for patients lags behind.
- The AHA statement outlines strategies to address this gap for healthcare professionals, communities, and policymakers.
- Medications and metabolic surgery are underutilized due to knowledge gaps, coverage limitations, and access issues.
- he stigma surrounding obesity hinders patient-provider communication and treatment adherence.
Furthermore, the authors said that connecting patients with recommendations within the community and utilizing technology as tools for information can help access for patients. To address cost effectiveness, they added that engaging stakeholders, the community, and health professionals in conversations to improved cost-effectiveness programs is essential.1
Finally, they stated that improving social and community support by providing treatment approaches focused on couples, family, and household, and offering connections to community groups that provide resources and support to patients, can also address these gaps in clinical care.1
“While significant strides have been made in advancing the science to help us understand obesity, there remains a considerable gap between what we know and what happens in the doctor’s office,” said Laddu in the press release. “Health care professionals and health care systems need to find better ways to put what we know about obesity into action so more people can get the right support and treatment. Adopting new technologies and telemedicine, making referrals to community-based weight management programs to encourage behavioral change, providing social support and increasing reach and access to treatments are just some of the promising methods we could implement to unlock successful, evidence-based obesity care.”2
References
Laddu D, Neeland IJ, Carnethon M, et al. Implementation of Obesity Science Into Clinical Practice: A Scientific Statement From the American Heart Association. Circulation. Published online May 20, 2024. doi:10.1161/CIR.0000000000001221
Significant gaps between science of obesity and the care patients receive. News release. American Heart Association. May 20, 2024. Accessed May 21, 2024. https://newsroom.heart.org/news/significant-gaps-between-science-of-obesity-and-the-care-patients-receive